Serving Overlooked PatientsSM

Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people.

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

ferabright Logo

Learn about FerabrightTM

Click for Full Prescribing Information,
including Indication, BOXED WARNING, and Important Safety Information.

PRODUCT ANNOUNCEMENT

Xifyrm Logo

Learn about JavadinTM

Click for Full Prescribing Information, including Indication and Additional Safety Information.

PRODUCT ANNOUNCEMENT

NOW AVAILABLE

ferabright Logo

Learn about FerabrightTM

Click for Full Prescribing Information, including Indication, BOXED WARNING, and Important Safety Information.

PRODUCT ANNOUNCEMENT

Xifyrm Logo

Learn about JavadinTM

Click for Full Prescribing Information, including Indication and Additional Safety Information.

OUR PRODUCTS

Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.

Explore all products

News & Events

Azurity Pharmaceuticals Announces FerabrightTM (ferumoxytol injection) Now Available in the U.S. for Magnetic Resonance Imaging of the Brain

Feb 26, 2026

Woburn, MA — February 26, 2026 — Azurity Pharmaceuticals, Inc. announced today that FerabrightTM (ferumoxytol injection) is now available in the U.S. Ferabright is the first and only iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.1 Ferabright was approved by the U.S. Food and Drug Administration (FDA) in October 2025.

read more

Azurity Pharmaceuticals Announces ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution, CII

Feb 10, 2026

Woburn, MA—February 10, 2026—Azurity Pharmaceuticals, Inc. announced that ARYNTA™ (lisdexamfetamine dimesylate) Oral Solution will be available mid-2026 for treating ADHD in adults and pediatric patients 6 years and older. Arynta, a ready-to-use lisdexamfetamine oral solution that may be stored at room temperature between 68°F to 77°F (20°C to 25°C),1 received FDA approval in June 2025.

read more
Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Show details Hide details
Functional and Performance Cookies

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Show details Hide details
Targeting Technologies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Show details Hide details
Powered by  GDPR Cookie Compliance